Studies show a 2- to 7-fold increased risk of NAION during Semaglutide therapy: Patients who received Semaglutide for the treatment of their diabetes had an approximately 2-fold increased risk
Tirzepatide (Mounjaro) MHRA-licensed for type 2 diabetes (NICE TA943) and, subject to ongoing NICE appraisal, potentially for obesity management
Proper technique, on the other hand, preserves this intricate structure, ensuring the peptide you use in your research is exactly what you intended it to be
Expert Medical Guidance: Our clinicians manage your dosage, monitor your progress, and help you navigate any potential side effects, ensuring your treatment is both effective and comfortable
Combined with pancreatic enzyme monitoring, you'll have a complete picture of how these medications affect your body